IMcode001: autogene cevumeran & pembrolizumab in melanoma

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, explores findings from the Phase II IMcode001 study (NCT03815058) of autogene cevumeran, an individualized neoantigen-specific mRNA immunotherapy, plus pembrolizumab versus pembrolizumab alone in patients with advanced melanoma. The combination did not significantly improve progression-free survival but was well tolerated. Most patients receiving autogene cevumeran developed neoantigen-specific immune responses, with broader responses associated with trends toward improved survival. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo